Medicovestor, Inc pioneers novel Antibody Drug Conjugate (ADC) platforms to bridge the therapeutic gaps of existing ADCs. It leverages the complementary expertise and extensive experience of each member of the team to maximize the probabilities of success and minimize risks. Led by a highly driven and dedicated C-suite, the strengths of the company include translational medicine leadership, protein/antibody engineering skills, US regulatory and clinical expertise, and a board-certified medical oncologist. Noteworthy experience encompasses healthcare venture capital, fast-paced start-up, healthcare product sales and marketing, and corporate financial management. The company's innovative ADoBind and ADoTope ADC platforms, hold potential to transform the landscape of ADCs, benefitting many disease indications and increasing the serviceable addressable markets. Its lead clinical programs are an ADoBind ADC for treating pancreatic cancer and ADoTope ADC for treating ovarian cancer.